Loading
Life sciences · Review
Journal of Clinical Medicine · September 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is a common and potentially modifiable barrier to heart transplant candidacy in patients supported by a durable left ventricular assist device (LVAD). Approximately 15% of LVAD recipients carry a body mass index (BMI) of 35 kg/m2 or greater; the 2024 International Society for Heart and Lung Transplantation guideline considers weight loss to a BMI below 35 kg/m2 reasonable before listing, within an individualized assessment, and only 18.6% of these patients achieve a 10% weight reduction through supportive care alone. Two interventions can close this gap. Anti-obesity medications, principally glucagon-like peptide-1 receptor agonists (GLP-1 RAs), reduce BMI gradually without a procedural intervention; however, the largest LVAD series reports a BMI reduction from 38.3 to 36.2 kg/m2 at one year with 26% of patients who began above 35 kg/m2 falling below it, and efficacy depends on continued adherence and insurance coverage. In the FIGHT trial, liraglutide showed a non-significant, numerically unfavorable signal in recently hospitalized patients with advanced heart failure with reduced ejection fraction who were not on mechanical support. Metabolic bariatric surgery, most often laparoscopic sleeve gastrectomy, delivers a BMI reduction of 6 to 10 kg/m2 within 6 to 12 months and was associated with a threefold higher probability of subsequent transplantation in an observational Medicare cohort, at the cost of serious 30-day complications in 11.3% of LVAD recipients compared with 2.5% of non-LVAD bariatric patients. This narrative review compares mechanisms, LVAD-specific liabilities, and published outcomes of both strategies, including cardiovascular and arrhythmic outcomes, and reframes the choice as a trade-off between the speed of BMI reduction and the distribution of risk over time. We propose a hypothesis-generating selection framework, based on expert opinion, that considers excess BMI above threshold, expected time on device, bleeding profile, and gastrointestinal tolerance, and we define the evidence gaps that a prospective study should address.